Innovative Drug Discovery and Nanotechnology (Track)
Albuvir, the First and Only New-Generation Anti-Viral Drug with Quick, Direct Effect and a Wide Spectrum of Activity
Sonya Sophya Farber Department of Drug Design and Nanotechnology
American Medical Technologies, Inc.
USA
Abstract:
Unlike antimicrobial drugs, there are almost no anti-viral drugs on the pharmaceutical market. This is notwithstanding the fact that more than 90% of animal pathology is connected with viruses. In many cases, anti-viral drugs have many side effects that are very difficult to correct (e.g., ribavarin with hepatitis C). Viruses are able to very quickly adapt to drugs that have long been used in the population and to newly created drugs (for example, Acyclovir). We have addressed these problems through substituting the classical, precisely conservative structure of anti-viral drugs for a dynamic, self-organizing system made of peptide molecules that are similar to but ultimately different from each other. The synthesized peptides have the properties of molecular robots; that is, they aggregate into a biologically active supramolecular complex when they have reached the tar-get. The quantity of fragments that are introduced into the organism is a multi-surplus quantity. This is necessary for the creation of conditions for the drug’s self-organization and self-adaptation to the organism and the viruses. In this case, the targets are the cellular and virally induced importins/exportins, the blockage of which will lead to a sharp decrease in viral replication in those vi-ruses whose cell cycles depend on the cell nucleus (if any kinds of viral fragment biosynthesizes in the cell nucleus). The drug Albuvir has shown high activity in relation to human viruses including influenza, coronavirus, herpes types 1 and 2, cytomegalovirus, the Epstein-Barr virus, and the he-patitis C virus. Use of the drug in volunteers with influenza led to phenomenal results: an effect from the use of the drug was observed after only 20 minutes: toxicopathy declined, appetite was restored, and body temperature was normalized. Long-term use of the drug in volunteer patients with hepatitis C led to a decrease in the viral titer from 5 to 102 over the 1.5 months of use of the drug; the size of the liver also normalized, as did liver function tests. Albuvir has shown high activity levels in the treatment of viral diseases in animals and is permitted for use as a veterinary anti-viral drug. Two years of use of the drug have not shown any toxic properties, while high biological activity has been demonstrated. The drug has shown high level activities against viral infec-tions such as the Newcastle Disease virus, the transmissible gastroenteritis virus, the classic swine pox virus, the African swine pox virus, the coronavirus, the vesicular stomatitis virus, the hoof-and-mouth disease virus, and others. Thus the drug we are proposing under the working name of Albuvir has a wide spectrum of anti-viral activity, is non-toxic, adapts independently to the host’s body and the virus, and does not cause resistance in the virus or the body. The components for the drug are accessible, and large-quantity production may be set up; the drug is ready to be presented for trials.
